Editorial
The role of osimertinib in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer
Abstract
Activating mutations in the epidermal growth factor receptor (EGFR) gene is the most common driver oncogene in non-small cell lung cancer (NSCLC), being present in up to 60% of Asian patients and up to 20% in Caucasian patients with advanced NSCLC.
